Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations

被引：0
|
作者：
Geng, R. [1 ]
Chen, Y. [1 ]
Miao, J. [2 ]
Liu, H. [1 ]
Qin, Y. [1 ]
Han, Z. [1 ]
Li, S. [1 ]
Guan, Y. [2 ]
Wu, H. [3 ]
Zhao, Y. [2 ]
Wang, Y. [1 ]
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Beijing Chao Yang Hosp, Beijing, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Furmonertinib; Stage I NSCLC; Adjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA15.13
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [1] Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors
    Li, X. -L.
    Wang, X.
    Fan, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S377 - S377
  • [2] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Shen, Zi-Qing
    Feng, Kun-Peng
    Fang, Zi-Yao
    Xia, Tian
    Pan, Shu
    Ding, Cheng
    Xu, Chun
    Ju, Sheng
    Chen, Jun
    Li, Chang
    Zhao, Jun
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [3] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Zi-Qing Shen
    Kun-Peng Feng
    Zi-Yao Fang
    Tian Xia
    Shu Pan
    Cheng Ding
    Chun Xu
    Sheng Ju
    Jun Chen
    Chang Li
    Jun Zhao
    Journal of Cardiothoracic Surgery, 19
  • [4] Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk Factors
    Choi, J.
    Choi, S. I.
    Oh, J. Y.
    Lee, Y. S.
    Min, K. H.
    Hur, G. Y.
    Shim, J. J.
    Park, D. W.
    Park, C. K.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S890 - S890
  • [5] Update on adjuvant therapy in completely resected NSCLC patients
    Lim, Jeong Uk
    Yeo, Chang Dong
    THORACIC CANCER, 2022, 13 (03) : 277 - 283
  • [6] Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease
    Liu, C.
    Han, Y.
    Leng, X.
    Yue, D.
    Zhao, G.
    Cheng, C.
    Li, G.
    Liang, N.
    Zhao, J.
    Liu, S.
    Huang, W.
    Wang, J.
    Liu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1617 - S1617
  • [7] Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors
    Wu, Q.
    Ni, M.
    Xue, F.
    Wu, X.
    Jiang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S545 - S545
  • [8] ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
    Sands, Jacob
    Mandrekar, Sumithra J.
    Oxnard, Geoffrey R.
    Kozono, David E.
    Hillman, Shauna L.
    Dahlberg, Suzanne Eleanor
    Sun, Zhuoxin
    Chaft, Jamie E.
    Govindan, Ramaswamy
    Gerber, David E.
    Gray, Jhanelle Elaine
    Malik, Shakun M.
    Mooney, Margaret M.
    Janne, Pasi A.
    Vokes, Everett E.
    Kelly, Karen
    Ramalingam, Suresh S.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2
    Tsutani, Yasuhiro
    Goldman, Jonathan W.
    Dacic, Sanja
    Yatabe, Yasushi
    Majem, Margarita
    Huang, Xiangning
    Chen, Allen
    van der Gronde, Toon
    He, Jie
    CLINICAL LUNG CANCER, 2023, 24 (04) : 376 - 380
  • [10] Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
    Zhang, Q.
    Ke, L.
    Huang, S.
    Yang, Y.
    He, T.
    Sun, H.
    Wu, Z.
    Zhang, X.
    Lv, W.
    Hu, J.
    Ye, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S555 - S556
12345